Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linezolid in the Treatment of Subjects With Nosocomial Pneumonia Proven to be Due to Methicillin-Resistant Staphylococcus Aureus.

Trial Profile

Linezolid in the Treatment of Subjects With Nosocomial Pneumonia Proven to be Due to Methicillin-Resistant Staphylococcus Aureus.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Linezolid (Primary) ; Vancomycin
  • Indications Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia
  • Focus Therapeutic Use
  • Acronyms ZEPHYR
  • Most Recent Events

    • 05 Jun 2017 Results characterizing resistance patterns in baseline methicillin-resistant Staphylococcus aureus (MRSA) isolates (n=427) presented at the ASM Microbe 2017
    • 18 May 2013 Results of the piggybacked economic analysis in the USA presented at the 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 27 Apr 2013 Results of a post-hoc economic analysis in Spain presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top